Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2016 2
2017 4
2018 4
2019 2
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

14 results
Results by year
Filters applied: . Clear all
Page 1
P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.
Najem A, Krayem M, Salès F, Hussein N, Badran B, Robert C, Awada A, Journe F, Ghanem GE. Najem A, et al. Among authors: Krayem M. Eur J Cancer. 2017 Sep;83:154-165. doi: 10.1016/j.ejca.2017.06.033. Epub 2017 Jul 21. Eur J Cancer. 2017. PMID: 28738256
Mesenchymal Stromal Cells and Toll-Like Receptor Priming: A Critical Review.
Najar M, Krayem M, Meuleman N, Bron D, Lagneaux L. Najar M, et al. Among authors: Krayem M. Immune Netw. 2017 Apr;17(2):89-102. doi: 10.4110/in.2017.17.2.89. Epub 2017 Apr 20. Immune Netw. 2017. PMID: 28458620 Free PMC article. Review.
Immunohematology Mesenchymal Stromal Cell-based Therapy: From Research to Clinic.
Najar M, Krayem M, Meuleman N, Bron D, Hélène B, Lagneaux L. Najar M, et al. Among authors: Krayem M. Appl Immunohistochem Mol Morphol. 2018 Mar;26(3):e26-e43. doi: 10.1097/PAI.0000000000000629. Appl Immunohistochem Mol Morphol. 2018. PMID: 29271793 Review.
Insights into inflammatory priming of mesenchymal stromal cells: functional biological impacts.
Najar M, Krayem M, Merimi M, Burny A, Meuleman N, Bron D, Raicevic G, Lagneaux L. Najar M, et al. Among authors: Krayem M. Inflamm Res. 2018 Jun;67(6):467-477. doi: 10.1007/s00011-018-1131-1. Epub 2018 Jan 23. Inflamm Res. 2018. PMID: 29362849 Review.
New Drug Combination Strategies in Melanoma: Current Status and Future Directions.
Najem A, Krayem M, Perdrix A, Kerger J, Awada A, Journe F, Ghanem G. Najem A, et al. Among authors: Krayem M. Anticancer Res. 2017 Nov;37(11):5941-5953. doi: 10.21873/anticanres.12041. Anticancer Res. 2017. PMID: 29061773 Review.
PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies.
Perdrix A, Najem A, Saussez S, Awada A, Journe F, Ghanem G, Krayem M. Perdrix A, et al. Among authors: Krayem M. Cancers (Basel). 2017 Dec 16;9(12):172. doi: 10.3390/cancers9120172. Cancers (Basel). 2017. PMID: 29258181 Free PMC article. Review.
Targeting prohibitin with small molecules to promote melanogenesis and apoptosis in melanoma cells.
Djehal A, Krayem M, Najem A, Hammoud H, Cresteil T, Nebigil CG, Wang D, Yu P, Bentouhami E, Ghanem GE, Désaubry L. Djehal A, et al. Among authors: Krayem M. Eur J Med Chem. 2018 Jul 15;155:880-888. doi: 10.1016/j.ejmech.2018.06.052. Epub 2018 Jun 23. Eur J Med Chem. 2018. PMID: 29960207
p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Salès F, van Kempen LC, Sibille C, Awada A, Marine JC, Ghanem G. Krayem M, et al. Eur J Cancer. 2016 Mar;55:98-110. doi: 10.1016/j.ejca.2015.12.002. Epub 2016 Jan 17. Eur J Cancer. 2016. PMID: 26790143
GLI inhibitor GANT61 kills melanoma cells and acts in synergy with obatoclax.
Vlčková K, Réda J, Ondrušová L, Krayem M, Ghanem G, Vachtenheim J. Vlčková K, et al. Among authors: Krayem M. Int J Oncol. 2016 Sep;49(3):953-60. doi: 10.3892/ijo.2016.3596. Epub 2016 Jul 1. Int J Oncol. 2016. PMID: 27572939
Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma.
Krayem M, Najem A, Journe F, Morandini R, Sales F, Awada A, Ghanem GE. Krayem M, et al. Oncotarget. 2018 Aug 7;9(61):31888-31903. doi: 10.18632/oncotarget.25879. eCollection 2018 Aug 7. Oncotarget. 2018. PMID: 30159130 Free PMC article.
14 results
Jump to page